BlueRock Therapeutics has created an automated system for high-throughput auditing of cell therapies, addressing a gap in existing solutions. This development is crucial for tech professionals as it pushes the boundaries of automation in a relatively new therapeutic modality, potentially lowering costs through reduced sample volumes and reagent usage. Other companies are encouraged to follow suit, driving further innovation in the field.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



